Literature DB >> 26188137

Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database.

David E Kaplan1, Feng Dai2, Ayse Aytaman3, Michelle Baytarian4, Rena Fox5, Kristel Hunt6, Astrid Knott7, Marcos Pedrosa4, Christine Pocha7, Rajni Mehta2, Mona Duggal2, Melissa Skanderson2, Adriana Valderrama8, Tamar H Taddei2.   

Abstract

BACKGROUND &
METHODS: The Child-Turcotte-Pugh (CTP) score is a widely used and validated predictor of long-term survival in cirrhosis. The CTP score is a composite of 5 subscores, 3 based on objective clinical laboratory values and 2 subjective variables quantifying the severity of ascites and hepatic encephalopathy. To date, no system to quantify CTP score from administrative databases has been validated. The Veterans Outcomes and Costs Associated with Liver Disease study is a multicenter collaborative study to evaluate the outcomes and costs of hepatocellular carcinoma in the U.S. Veterans Health Administration. We developed and validated an algorithm to calculate electronic CTP (eCTP) scores by using data from the Veterans Health Administration Corporate Data Warehouse.
METHODS: Multiple algorithms for determining each CTP subscore from International Classification of Diseases version 9, Common Procedural Terminology, pharmacy, and laboratory data were devised and tested in 2 patient cohorts. For each cohort, 6 site investigators (Boston, Bronx, Brooklyn, Philadelphia, Minneapolis, and West Haven VA Medical Centers) were provided cases from which to determine validity of diagnosis, laboratory data, and clinical assessment of ascites and encephalopathy. The optimal algorithm (designated eCTP) was then applied to 30,840 cirrhotic patients alive in the first quarter of 2008 for whom 5-year overall and transplant-free survival data were available. The ability of the eCTP score and other disease severity scores (Charlson-Deyo index, Veterans Aging Cohort Study index, Model for End-Stage Liver Disease score, and Cirrhosis Comorbidity) to predict survival was then assessed by Cox proportional hazards regression.
RESULTS: Spearman correlations for administrative and investigator validated laboratory data in the HCC and cirrhotic cohorts, respectively, were 0.85 and 0.92 for bilirubin, 0.92 and 0.87 for albumin, and 0.84 and 0.86 for international normalized ratio. In the HCC cohort, the overall eCTP score matched 96% of patients to within 1 point of the chart-validated CTP score (Spearman correlation, 0.81). In the cirrhosis cohort, 98% were matched to within 1 point of their actual CTP score (Spearman, 0.85). When applied to a cohort of 30,840 patients with cirrhosis, each unit change in eCTP was associated with 39% increase in the relative risk of death or transplantation. The Harrell C statistic for the eCTP (0.678) was numerically higher than those for other disease severity indices for predicting 5-year transplant-free survival. Adding other predictive models to the eCTP resulted in minimal differences in its predictive performance.
CONCLUSION: We developed and validated an algorithm to extrapolate an eCTP score from data in a large administrative database with excellent correlation to actual CTP score on chart review. When applied to an administrative database, this algorithm is a highly useful predictor of survival when compared with multiple other published liver disease severity indices.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Child-Turcotte-Pugh Score; Cirrhosis; Database; Hepatitis C; Hepatocellular Carcinoma; Human; Natural History; Survival

Mesh:

Year:  2015        PMID: 26188137      PMCID: PMC4655141          DOI: 10.1016/j.cgh.2015.07.010

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  28 in total

Review 1.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

2.  Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study.

Authors:  Vincent Lo Re; Joseph K Lim; Matthew Bidwell Goetz; Janet Tate; Harini Bathulapalli; Marina B Klein; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; Sheldon T Brown; Farah Kidwai; Cynthia Brandt; Zachariah Dorey-Stein; K Rajender Reddy; Amy C Justice
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-05-27       Impact factor: 2.890

3.  Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.

Authors:  Daniel B Brown; Christopher E Fundakowski; Mauricio Lisker-Melman; Jeffrey S Crippin; Thomas K Pilgram; William Chapman; Michael D Darcy
Journal:  J Vasc Interv Radiol       Date:  2004-11       Impact factor: 3.464

4.  A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data.

Authors:  Hajime Uno; Lu Tian; Tianxi Cai; Isaac S Kohane; L J Wei
Journal:  Stat Med       Date:  2012-10-05       Impact factor: 2.373

5.  Predicting in-hospital mortality in patients with cirrhosis: results differ across risk adjustment methods.

Authors:  Robert P Myers; Hude Quan; James N Hubbard; Abdel Aziz M Shaheen; Gilaad G Kaplan
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

6.  Predictive indices of morbidity and mortality after liver resection.

Authors:  Rebecca A Schroeder; Carlos E Marroquin; Barbara Phillips Bute; Shukri Khuri; William G Henderson; Paul C Kuo
Journal:  Ann Surg       Date:  2006-03       Impact factor: 12.969

7.  Utilization of screening for hepatocellular carcinoma in the United States.

Authors:  Jessica A Davila; Allan Weston; Walter Smalley; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2007-09       Impact factor: 3.062

8.  Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease.

Authors:  Adnan Said; John Williams; Jeremy Holden; Patrick Remington; Ronald Gangnon; Alexandru Musat; Michael R Lucey
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

9.  Laparoscopic cholecystectomy in cirrhotic patients: the value of MELD score and Child-Pugh classification in predicting outcome.

Authors:  Spiros Delis; Andreas Bakoyiannis; Juan Madariaga; John Bramis; Nikos Tassopoulos; Christos Dervenis
Journal:  Surg Endosc       Date:  2009-06-24       Impact factor: 4.584

10.  Accuracy and completeness of mortality data in the Department of Veterans Affairs.

Authors:  Min-Woong Sohn; Noreen Arnold; Charles Maynard; Denise M Hynes
Journal:  Popul Health Metr       Date:  2006-04-10
View more
  51 in total

1.  Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States.

Authors:  David E Kaplan; Michael K Chapko; Rajni Mehta; Feng Dai; Melissa Skanderson; Ayse Aytaman; Michelle Baytarian; Kathryn D'Addeo; Rena Fox; Kristel Hunt; Christine Pocha; Adriana Valderrama; Tamar H Taddei
Journal:  Clin Gastroenterol Hepatol       Date:  2017-07-26       Impact factor: 11.382

2.  Quality Measures, All-Cause Mortality, and Health Care Use in a National Cohort of Veterans With Cirrhosis.

Authors:  Marina Serper; David E Kaplan; Justine Shults; Peter P Reese; Lauren A Beste; Tamar H Taddei; Rachel M Werner
Journal:  Hepatology       Date:  2019-06-26       Impact factor: 17.425

3.  Risk prediction scores for acute on chronic liver failure development and mortality.

Authors:  Nadim Mahmud; Rebecca A Hubbard; David E Kaplan; Tamar H Taddei; David S Goldberg
Journal:  Liver Int       Date:  2019-12-26       Impact factor: 5.828

4.  Liver-related mortality is similar among men and women with cirrhosis.

Authors:  Nikhilesh R Mazumder; Stela Celaj; Kofi Atiemo; Amna Daud; Kathryn L Jackson; Abel Kho; Josh Levitsky; Daniela P Ladner
Journal:  J Hepatol       Date:  2020-04-25       Impact factor: 25.083

5.  Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.

Authors:  Kim A Reiss; Shun Yu; Ronac Mamtani; Rajni Mehta; Kathryn D'Addeo; E Paul Wileyto; Tamar H Taddei; David E Kaplan
Journal:  J Clin Oncol       Date:  2017-09-05       Impact factor: 44.544

6.  Incidence and Mortality of Acute-on-Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis.

Authors:  Nadim Mahmud; David E Kaplan; Tamar H Taddei; David S Goldberg
Journal:  Hepatology       Date:  2019-03-20       Impact factor: 17.425

7.  The Child-Turcotte Classification: From Gestalt to Sophisticated Statistics and Back.

Authors:  Guadalupe Garcia-Tsao
Journal:  Dig Dis Sci       Date:  2016-11       Impact factor: 3.199

8.  Mailed Outreach Program Increases Ultrasound Screening of Patients With Cirrhosis for Hepatocellular Carcinoma.

Authors:  Amit G Singal; Jasmin A Tiro; Jorge A Marrero; Katharine McCallister; Caroline Mejias; Brian Adamson; Wendy Pechero Bishop; Noel O Santini; Ethan A Halm
Journal:  Gastroenterology       Date:  2016-11-05       Impact factor: 22.682

9.  Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation.

Authors:  Marina Serper; Ethan M Weinberg; Jordana B Cohen; Peter P Reese; Tamar H Taddei; David E Kaplan
Journal:  Hepatology       Date:  2020-11-09       Impact factor: 17.425

10.  Primary biliary cirrhosis degree assessment by acoustic radiation force impulse imaging and hepatic fibrosis indicators.

Authors:  Hai-Chun Zhang; Rong-Fei Hu; Ting Zhu; Ling Tong; Qiu-Qin Zhang
Journal:  World J Gastroenterol       Date:  2016-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.